Concentrations of factor VIII‐related antigen and factor XIII during open heart surgery

Brody, Jerome I.; Pickering, Nancy J.; Fink, G

doi:10.1046/j.1537-2995.1986.26587020130.x

Cited by 19 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During adult cardiac surgery, a drop of factor XIII between 30% and 50% is seen as expected by the average degree of hemodilution (approximately 25%). In a neonate, because of size, the expected degree of hemodilution is well around 60% .…”

Section: Discussionmentioning

confidence: 78%

The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery

Gertler

Martin

Hapfelmeier

et al. 2013

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 78%

The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery

Gertler

Martin

Hapfelmeier

et al. 2013

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

“…A large literature has developed indicating that acquired FXIII deficiency is not uncommon, especially in certain surgical settings [5,6,8,9] and gut-associated inflammatory processes [12][13][14], and preliminary data suggest that administration of FXIII may provide therapeutic benefit in some of Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration 927 these settings [7,11]. The availability of a well-characterized recombinant product would allow for further clinical investigation of the response of these disease states to administration of FXIII.…”

Section: Discussionmentioning

confidence: 99%

Safety, pharmacokinetics, and immunogenicity of single‐dose rFXIII administration to healthy volunteers

Reynolds

Butine

Visich

et al. 2005

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary. Background: Factor XIII (FXIII) is a transglutaminase that cross-links fibrin and other proteins to improve clot strength and resistance to fibrinolysis. Both congenital and acquired FXIII deficiency may result in a bleeding diathesis, and plasma-derived FXIII has been used to treat many of these clinical conditions. Objectives: A clinical study was designed and performed to evaluate the safety, pharmacokinetics, and immunogenicity of recombinant FXIII (rFXIII) administration to healthy adult volunteers. Patients and methods: Fifty healthy adult volunteers were enrolled in this randomized, double-blinded, placebo-controlled study. A single dose of rFXIII, ranging from 2 U kg )1 to 50 U kg, or placebo was administered. Safety was evaluated by capturing adverse events, clinical safety laboratory studies, and clinical score for deep venous thrombosis. Blood samples were taken for pharmacokinetic and immunogenicity analysis throughout the 28-day follow-up period. Results: Recombinant FXIII was well tolerated, with no serious adverse events or doserelated toxicities. Following a single i.v. injection of 50 U kg )1 rFXIII, the estimated terminal half-life was 270-320 h, the volume of distribution ranged from 40 to 75 mL kg )1, and FXIII activity increased 1.77% per 1 U kg )1 rFXIII administered. Increase in circulating A 2 B 2 and decrease in free FXIII-B subunit indicate in vivo formation of FXIII heterotetramer. An immunogenic response to rFXIII or yeast, the production host, was not observed. Conclusions: Recombinant FXIII was well tolerated at doses of up to 50 U kg )1 in healthy adult volunteers. The safety, pharmacological and immunological profile of rFXIII suggests it should be studied in patients with congenital FXIII deficiency as well as evaluated as a systemic hemostat in patients with acquired FXIII deficiency or hemorrhage.

show abstract

“…Acquired factor XIII deficiency is common following cardiopulmonary bypass (147)(148)(149)(150) and children may be particularly susceptible to the deficiency. In children undergoing open heart surgery for congenital cardiac defects, those with low factor XIII levels have a higher risk for developing myocardial edema requiring delayed sternal closure (151).…”

Section: Role Of Transglutaminases In Vascular Permeabilitymentioning

confidence: 99%

Roles of transglutaminases in cardiac and vascular diseases

Sane

Kontos²,

Greenberg³

2007

Front Biosci

View full text Add to dashboard Cite

All transglutaminases share the common enzymatic activity of transamidation, or the cross-linking of glutamine and lysine residues to form N epsilon (gamma-glutamyl) lysyl isopeptide bonds. The plasma proenzyme factor XIII is responsible for stabilizing the fibrin clot against physical and fibrinolytic disruption. Another member of the transglutaminase family, tissue transglutaminase or TG2 is abundantly expressed in cardiomyocytes, vascular cells and macrophages. The transglutaminases have a variety of functions independent of their transamidating activity. For example, TG2 binds and hydrolyzes GTP, thereby fostering signal transduction by several G protein coupled receptors. Accumulating evidence points to novel roles for factor XIII and TG2 in cardiovascular biology including: (a) modulating platelet activity, (b) regulating glucose control, (c) contributing to the development of hypertension, (d) influencing the progression of atherosclerosis, (e) regulating vascular permeability and angiogenesis (f) and contributing to myocardial signaling, contractile activity and ischemia/reperfusion injury. In this review, we summarize the cardiovascular biology of two members of the family of transglutaminases, Factor XIII and TG2.

show abstract

Concentrations of factor VIII‐related antigen and factor XIII during open heart surgery

Cited by 19 publications

References 6 publications

The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery

The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery

Safety, pharmacokinetics, and immunogenicity of single‐dose rFXIII administration to healthy volunteers

Roles of transglutaminases in cardiac and vascular diseases

Contact Info

Product

Resources

About